Ambrx Biopharma Debt to Equity Ratio 2020-2022 | AMAM
Current and historical debt to equity ratio values for Ambrx Biopharma (AMAM) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ambrx Biopharma debt/equity for the three months ending June 30, 2022 was 0.00.
|Ambrx Biopharma Debt/Equity Ratio Historical Data
||Long Term Debt
||Debt to Equity Ratio
||Medical - Biomedical and Genetics
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.